Market research
ALKS Alkermes Plc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 8B
- P/E ratio
- 127.18
- Analyst target
- 56
- Dividend yield
- Not available
- Beta
- 0.27
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- USG017671052
- Market cap
- 8B
- P/E ratio
- 127.18
- Analyst target
- 56
- Dividend yield
- Not available
- Beta
- 0.27
About
About Alkermes Plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALKS discussion.
5 years, 4 months ago
Alkermes plc is currently in a long term uptrend where the price is trading 24.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.9.
Alkermes plc's total revenue sank by 32.2% to $280M since the same quarter in the previous year.
Its net income has dropped by 696.5% to $-43M since the same quarter in the previous year.
Finally, its free cash flow grew by 512.9% to $62M since the same quarter in the previous year.
Based on the above factors, Alkermes plc gets an overall score of 3/5.